A venture capital firm with offices in the Bay area invests in a wide variety of industries and is currently making investments from two separate funds that total to $700M: one being a venture fund investing primarily in Series A and B rounds, and a fund investing in growth stage opportunities. The firm is flexible in investment structure, with typical Series A investments of $5M – $10M upfront with capital reserved for subsequent rounds. The firm usually leads investments and seeks a board seat, but may also invest as part of larger syndicates. The firm is active in their portfolio companies and seeks to add value through network, recruiting, and experience in startup strategy and operations. The firm will invest globally.

The firm is open to investing in multiple sectors, but has a strategic focus in life sciences and digital health. The firm has special interest in therapeutics (especially platform technologies), digital health (especially digital therapeutics and chronic care management) genomics, and synthetic biology.

The firm believes passionately that their role is to support and serve great management teams and entrepreneurs.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

An early stage investment firm with offices in North America and Asia focuses on facilitating the development and commercialization of high-potential, high-impact life science innovations arising from the U.S., Canada, South Korea, China and other markets that represent a significant source of opportunities for outsized value creation. The firm makes initial seed investments of US$100K – 1M and can bring in strategic capital from Asia to facilitate global development and market entry. The firm expects to make 2-3 new investments in the coming year.

Within life sciences, the firm is mostly interested in therapeutics, molecular diagnostics and digital health. The firm takes an opportunistic approach when it comes to disease areas and targets early stage innovation on the cusp of preclinical proof-of-concept or validation.

The firm is looking for capable teams developing innovative technologies. The firm works actively with entrepreneurs to devise and implement development and commercialization strategies, help assemble management personnel, and secure additional capital. For more mature opportunities, the firm will add value by using its fundraising, monetization, business development and licensing expertise to help secure investments and partnerships that will fund and expedite eventual commercialization.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A Silicon Valley-based venture capital firm founded in 2012 currently has $300M AUM and investing from its third, $100M fund. The firm focuses on early-stage investments from Seed to Series A, and initial size of investment can range from $500K to up to $3M. The firm reserves a significant part of the fund as follow-on investment. With the current fund, the firm seeks to invest in a total of 6-8 companies, with a preference for companies that are within proximity to their office in the Bay area.

The firm is interested in technologies that incorporate mobility and data. In terms of life sciences and healthcare, this includes digital health, AI and big data in discovery, precision medicine, etc. The firm has made several investments in digital health companies – examples include a mobile coaching app that promotes smarter decisions and better outcomes, a digital health platform for chronic disease management, etc.

The firm looks for driven management teams – relevant industry experience is a definite plus, but not an absolute requirement. The firm works closely with portfolio companies, providing companies with the needed resources and expertise to achieve scalability. The firm prefers to act as the lead investor, typically taking a board seat in such cases.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A strategic capital group within a large company is focused on venture and growth stage investments in several verticals including healthcare, IT and energy. The group will make investments from $5M – $30M and is very flexible with structure and size, with approximately 80% of investments in the form of equity and the other 20% in debt. The group will both lead or co-invest and typically seeks board representation although it is not a requirement. The group is focused on companies in the United States, but may look at some international opportunities in select geographies.

The firm is interested in medical devices, healthcare services, digital health, and biopharma and the group is looking for derisked opportunities in these areas. In the medical device space, the group is interested in devices that have achieved FDA approval and have reimbursement established. Digital health/healthcare IT companies should have commercial traction and a minimum of 10-20 paying customers. The group is looking for healthcare services companies that have proven their business model and are in need of growth capital. In the biopharma space, the group avoids opportunities with binary scientific, development, or clinical risk and is interested in areas such as specialty pharma, outsourced services, platform technologies, etc.

The firm places a large emphasis on high quality management teams and will work with companies with an incomplete management team as long as the key members of management are in place and have significant experience/expertise in the area they are pursuing.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A large pharmaceutical company based in China is fully integrated with solid infrastructures in drug development, clinical development, regulatory, manufacturing, sales and marketing in China with global perspectives. The firm currently manages two funds with over $200 million AUM and is actively seeking investment opportunities across a wide range of industries. A significant allocation of the fund is dedicated to healthcare and life sciences investments, while the rest of the fund will focus on investing in electronic materials and aluminum business. On average, the size of investment is $10M, but the firm has the capacity to invest more in companies they identify as a strong fit. The firm can invest in a broad variety of types and transaction structures including growth capital, buyouts, late-stage developments (with proof of concept), and recapitalizations. The firm looks for companies located around the globe, with a preference in the US, Europe, and Japan.

The firm is a flexible and opportunistic investor that is currently considering Therapeutics, Medical Devices, and Diagnostics. The firm is open to all kinds of sectors and indications with preferences in antivirus, oncology, neurosciences, and diabetes. The firm is open to novel medical devices of all FDA regulatory pathways, including 510k and PMA. The firm is strongly interested in medical devices. In terms of therapeutics, the firm will look at products of all stages from pre-clinical to phase I, and from phase III to on-the-market; while middle stage products might be a less focus. Regarding medical devices and diagnostics, the firm will invest at any stage of development. The firm is willing to consider companies targeting orphan indications.

The firm can invest in both private and public companies. The firm is willing to both lead and co-invest in companies located around the globe, while co-invest is their sweet spot. The firm has no specific requirements for the management team. The firm may take a board seat in applicable cases.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A USA based medical technology venture firm founded in 2013 makes equity investments in early stage companies developing products for to accelerate the trend of precision medicine diagnostics. The firm seeks a leading investment position and deep involvement with its portfolio companies. Typical investment ranges from $5-15 M and is calibrated to milestone attainment. With a global view and global operational capabilities, the firm is currently seeking opportunities around the world.

The firm focuses on three market segments that support knowledge-generating precision medicine diagnosis: 1) mobile health, data analytics, and healthcare IT; 2) high specificity in-vivo and in-vitro diagnostics; and 3) diagnostic technologies that guide or are a companion to precision therapies. The firm is looking for technologies that will dramatically improve patient health and have the potential for global markets and scale.

The firm is looking for experienced management teams with deep domain expertise. The firm typically request board representation post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.